Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118522
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118522
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118522
Figure 2 Comparative analysis of objective response rate and conversion success rates using Response Evaluation Criteria in Solid Tumors and modified Response Evaluation Criteria in Solid Tumors assessment criteria.
mRECIST: Modified Response Evaluation Criteria in Solid Tumors; ORR: Objective response rate; RECIST: Response Evaluation Criteria in Solid Tumors.
- Citation: Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522
- URL: https://www.wjgnet.com/1948-5204/full/v18/i7/118522.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.118522